CCR2 and neoplasm: Given the multiple reports that have classified CCL2 expression as having a role in the accumulation of CCR2+ TAMs in the PDAC TME, which has been associated with a decreased prognosis, trials have been initiated to understand if blocking CCR2 enhances anti-tumor effects in PDAC.